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S U M M A R Y
Objectives: To detect father-to-fetus transmission of hepatitis B virus (HBV) in utero.
Methods: We conducted a study at the prenatal diagnosis center of Taizhou City. Fetuses with one or
both parents carrying the hepatitis B surface antigen (HBsAg) were identiﬁed before genetic testing
during the period 2008–2010. Intrauterine samples were obtained by amniocentesis or cordocentesis
and tested for serological markers and by quantitative DNA assays. All neonates received combined
hepatitis B immunoprophylaxis after delivery, and serological follow-up tests were performed at 1 year
of age.
Results: Of the 407 couples enrolled in the study, HBV was carried by fathers only in 164, and none of
their fetuses were found to be HBV DNA-positive in utero. All fetal serological markers were found to be
of maternal but not paternal origin. The response rate to postnatal vaccination was 98.6%, and none of the
children who failed immunoprophylaxis were the offspring of the HBV carrier fathers.
Conclusions: The infection of fetuses with HBV from the spermatozoa of carrier fathers seems unlikely,
especially in an area where pre-conception hepatitis B vaccination is routinely provided.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Transmission of the hepatitis B virus (HBV) from mother to
infant is the predominant route in most high prevalence areas such
as China.1 However, father-to-child transmission also plays an
important role in the prevalence of hepatitis B.2 The transmission
of HBV infection to children from their carrier fathers could be
either horizontal through intimate postnatal contact, or vertical via
the male germ line.3 The latter is considered an intrauterine
infection. However, whether this really exists in humans remains
to be determined.
In past decades, several studies have reported the presence of
integrated HBV DNA in human spermatozoal chromosomes.4,5
Studies on embryos hybridized with mammalian ova and human
spermatozoa have also conﬁrmed that sperm-integrated HBV DNA
can replicate and express the HBV protein in two-cell hybrid
embryos.6–8 All of the above ﬁndings demonstrate that theoretically
the father could transmit HBV to the fetus via their spermatozoa.
Since HBV is a blood-borne virus, unvaccinated pregnant
women would be at risk of HBV exposure if their fetuses carried the
virus from the fathers. On the other hand, maternal antibodies can§ ClinicalTrials.gov ID: NCT01574521.
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http://dx.doi.org/10.1016/j.ijid.2012.09.002pass through the placenta and enter the fetal circulation freely. If
women are vaccinated for HBV prior to conception, and thus HBV-
negative, it still needs to be determined what would happen to the
maternal immune system if the fetus contracted HBV as a result of
HBV-positive spermatozoa. Would the fetus be passively immu-
nized due to hepatitis B immune globulin (HBIG) leaking from the
maternal circulation? However, because the literature on the
transmission of HBV by spermatozoa in vivo is scarce, the viral
replicating status and fetal immune response in utero are
unknown. Only one study has detected HBV DNA and serological
makers in eight aborted fetuses with a suspected HBV transmission
via spermatozoa,9 but the sample size of the study was small and
the maternal serological status was uncertain.
Specimens used for the evaluation of intrauterine infection
include amniotic ﬂuid, placental tissue,10–13 and neonatal periph-
eral blood.14–17 Because the postnatal sample is inevitably
contaminated by the maternal blood during delivery, this would
be of no use in the determination of the time when the infection
occurred (before or during delivery). A better alternative is to
detect fetal infection before delivery by prenatal diagnostic
techniques. Compared to postnatal specimens, intrauterine speci-
mens obtained from amniocentesis or cordocentesis can minimize
the risk of contamination with maternal blood.18 These techniques
are also safe and the risk of nosocomial infection caused by
invasive procedures is very low.19–22ses. Published by Elsevier Ltd. All rights reserved.
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seroepidemiology by prenatal diagnostic technique and to seek
evidence of HBV vertical transmission via spermatozoa.
2. Materials and methods
We conducted a prospective study at Taizhou Hospital of
Zhejiang Province, a large prenatal diagnosis center with more
than 2000 invasive procedures performed every year. The
institutional review committees and ethics committees for
reproductive medicine approved this study. The research involved
pregnant women who received prenatal diagnosis during the
period January 2008 to June 2010. Women and their husbands
were screened for HBsAg before genetic testing. HBV carriers were
identiﬁed and their fetuses were recruited to test for intrauterine
infection. With regard to the women who were probably carrying
an HBV carrier fetus, a supplemental informed consent form was
signed following a full discussion on the risk of maternal HBV
exposure due to the invasive procedure. The indications for
amniocentesis are: screening when there is a high risk of Down
syndrome, advanced maternal age, familial genetic disease,
previous child with chromosome abnormalities, and where there
are sonographic markers for chromosome abnormalities. The475 c
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Figure 1. Flow chart of indications for cordocentesis are: rapid karyotyping, diagnosis of
fetal thalassemia, and blood chemistry. Amniocenteses were
performed between gestational weeks 16 and 23, and cordocent-
eses were performed between gestational weeks 22 and 32. Only
women with an indication for amniocentesis or cordocentesis
were recruited. Samples from ﬁrst trimester invasive procedures,
such as chorionic villous sampling (CVS), were not included
because it was difﬁcult to get enough specimens for analysis.
Amniocenteses and cordocenteses were performed using 22-
gauge spinal needles, free-hand manipulation, and continuous
ultrasound guidance. To obtain a pure fetal specimen, the ﬁrst
syringe of amniotic ﬂuid was discarded to avoid a ‘blood-tip’ and
transplacental puncture was avoided if possible. Fetal blood
samples were collected from the ﬂoating cord and veriﬁed by
hemoglobin electrophoresis, which can identify the maternal
hemoglobin (HbA2) within the fetal sample.
After having collected enough specimens for genetic analysis, a
further 0.5–1 ml of sample was extracted by ﬁnal syringe for
hepatitis B serological and HBV DNA tests. Specimens for HBV DNA
analysis were stored at 20 8C until assay, and serological tests
were performed immediately after the puncture. If an intrauterine
infection was detected, post-exposure prophylaxis combined with
HBIG and hepatitis B vaccine was administered immediately forouples with eithe r or both 
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study participants.
Table 1
Serology of the HBV carrier parents
Markersa HBsAg-positive
father (n = 181)
HBsAg-positive
mother (n = 243)
HBsAg positive 181 (100%) 243 (100%)
HBeAg positive 51 (28.2%) 86 (35.4%)
anti-HBe positive 130 (71.8%) 157 (64.6%)
anti-HBc positive 181 (100%) 243 (100%)
HBV DNA positive 69 (38.1%) 98 (40.3%)
HBV DNA levels
(log10 copies/ml)
7.044  1.56 6.702  1.74
HBsAg, hepatitis surface antigen; HBeAg, hepatitis B e antigen; anti-HBe, hepatitis B
e antibody; anti-HBc, hepatitis B core antibody; HBV, hepatitis B virus.
a No signiﬁcant differences were found in the serology of carrier fathers and
mothers.
Table 2
Serological test results of fetal samples from prenatal diagnosis
Fetal serology HBsAg carrier status of parents
Only father
carrier
(n = 164)
Both parents
carriers
(n = 17)
Only mother
carrier
(n = 226)
HBsAg positive 0a 1 15
HBeAg positive 0a 4 35
anti-HBs positive 79a 0 0
anti-HBe positive 0a 2 26
anti-HBc positive 5a 12 141
All HBV markers negative 80 2 36
HBV DNA positive 0a 0 11
Titers of HBV DNA
(log10 copies/ml)
- - 3.179  0.36
HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; anti-HBs, hepatitis
B surface antibody; anti-HBe, hepatitis B e antibody; anti-HBc, hepatitis B core
antibody; HBV, hepatitis B virus.
a p < 0.05.
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nated if chromosomal anomalies were conﬁrmed, and fetal liver
tissues were taken for HBV DNA analyses at autopsy. All neonates
received vaccines according to the guidelines of the national
hepatitis B immunization program. Three doses of recombinant
vaccine were given on a 0-, 1-, and 6-month schedule, and 100 IU of
HBIG was administrated within 24 h after birth. A post-vaccination
efﬁcacy evaluation was performed 6 months after the immuniza-
tion series.
Serological markers (hepatitis B surface antigen (HBsAg),
hepatitis B e antigen (HBeAg), hepatitis B surface antibody (anti-
HBs), hepatitis B e antibody (anti-HBe), and hepatitis B core
antibody (anti-HBc)) were assessed by enzyme immunoassays
(AxSYM; Abbott Laboratories, Chicago, IL, USA). HBV DNA was
extracted by alkaline lysis method and the DNA analysis was
performed by ﬂuorescence quantitative PCR (FQ-PCR).16 PCR kits
were produced by Shanghai ShenYou Biological Technique
Company Inc. The PCR ampliﬁcation was performed using an
ABI Prism 310 Genetic Analyzer at 94 8C for 5 min, then 40 cycles of
94 8C for 5 s, 60 8C for 40 s, and 72 8C for 30 s, followed by 72 8C for
5 min. The lower limit of detection of the PCR was 100 IU/ml (1 IU/
ml = 5.26 copies/ml).
The statistical analysis was performed using SPSS 16.0 software
package. Continuous variable measures are presented as the mean
and standard deviation. Statistical tests used were the t-test and
Chi-square or Fisher’s exact test; a p-value of <0.05 was considered
statistically signiﬁcant.
3. Results
3.1. General
A total of 407 couples consented to participate in this study and
have their fetal samples retrieved; a ﬂow diagram showing study
participation is shown in Figure 1. Among these couples, 181
fathers and 243 mothers were HBV carriers, with 17 couples having
both father and mother HBsAg carriers. Eight fathers donated their
sperm for HBV DNA analysis and three samples were found to be
HBV DNA-positive. However, the average seminal HBV DNA titer
was 6.801  1.67 log10 copies/ml, which was similar to their serum
DNA levels. There was no signiﬁcant difference in the hepatitis B
serological tests between carrier fathers and mothers (Table 1).
3.2. Analysis of the fetal sample
Amniocenteses were performed on 338 pregnant women
whose mean gestational age at the puncture was 20.9  1.1 weeks.
Another 69 women underwent cordocentesis, and the mean
gestational age at puncture was 28.2  3.7 weeks. HBV serology
and DNA levels in the intrauterine samples are presented in Table 2.
No serological evidence of prenatal infection was found in fetuses
whose fathers carried HBV but whose mothers were HBV-negative.
Moreover, no matter what the father’s carrier status, only fetuses of
seropositive mothers had hepatitis B markers in utero. Of the fetusesTable 3
Serology of parents who were both carriers and their seropositive fetuses
Case Fetal serology Father’s serolog
HBsAg HBeAg DNAa HBsAg 
1 Pos Pos Neg Pos 
2 Neg Pos Neg Pos 
3 Neg Pos Neg Pos 
4 Neg Pos Neg Pos 
HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; Pos, positive; Neg, ne
a DNA = HBV DNA level in log10 copies/ml.whose parents were both carriers, four were found to be HBeAg-
positive. However, in all cases the fetal HBeAg was of maternal origin
(Table 3). Actually, the HBV serology or DNA expressed in the uterus
was completely matched to the maternal serological status, therefore
this result implies that the fetal immune system was unable to
produce hepatitis markers by itself.
3.3. Follow-up and children with chronic hepatitis B infection
Eight pregnancies were terminated because of a chromosom-
al anomaly (ﬁve cases) or multiple malformations (three cases),
and the fetal liver tissues were taken for HBV DNA analysis
during autopsy. Similar to the prenatal serology, none of HBV
DNA detected in liver specimens was linked to carrier fathers.
Most of the genetically normal fetuses went to full term, except
for three preterm births that occurred due to premature rupture
of the membranes. All neonates were vaccinated at birth, and 319
of them underwent post-vaccination tests at 1 year of age; the
follow-up rate was 79.9%. A persistent HBsAg carrier state wasy Maternal serology
HBeAg DNAa HBsAg HBeAg DNAa
Neg Neg Pos Pos 8.735
Neg Neg Pos Pos 6.901
Neg Neg Pos Pos 7.254
Neg Neg Pos Pos 7.604
gative; HBV, hepatitis B virus.
Table 4
Post-vaccination serological tests at 1 year of age
HBV markers of children HBsAg carrier status of parents
Only father
carrier
(n = 126)
Both parent
carriers
(n = 15)
Only mother
carrier
(n = 178)
anti-HBs positive 124 15 164
HBsAg positivea 0 0 6
Both negative 2 0 8
HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; anti-HBs, hepatitis B
surface antibody.
a p < 0.05.
Q.-X. Cai, Y.-Y. Zhu / International Journal of Infectious Diseases 17 (2013) e54–e58 e57observed in six children who were born to HBV carrier mothers.
For children of HBsAg carrier fathers’ the vaccine response rate
was 98.6%, and none of them were persistent HBsAg carriers
(Table 4).
4. Discussion
This is the ﬁrst fetal seroepidemiological and virological report
on the transmission of HBV via spermatozoa. However, we found
no reliable evidence to support the hypothesis that the father can
transmit HBV to the fetus via the male germ line. In contrast to the
previous literature,9 none of the 11 HBV DNA-positive fetuses were
born to carrier fathers in our study. Furthermore, neither fetal
serology nor the immune response was associated with the father’s
carrier status. The national hepatitis B vaccination program was
launched in 1992,23 and many Chinese women today were
vaccinated in childhood. In the present study, 90% of the wives
of HBV carrier husbands were detected to be anti-HBs-positive and
this antibody was also found in the uterus in 70.5% of them. Thus,
we hypothesize that the maternal immune system might
contribute to rapidly clear the small amount of virus carried by
spermatozoa or replicated in the embryo.
However, the mechanism of fetal hepatocyte maturation also
does not support HBV mass replication at an early gestational age.
The fetal liver does not begin to develop until week 12 of
gestation.24 An in vitro study showed that early stage human
hepatocytes cannot be infected with HBV without induced
maturation.25 Because Dane particle assembly in the fetal
hepatocyte can only occur in late pregnancy, thus postnatal
immunization would still effectively to clear the small amount of
virus carried from the spermatozoa. This hypothesis could also
explain why fetal infection has only rarely been caused by a middle
trimester invasive procedure.
In fact, we never detected any HBV DNA or serological markers
in fetuses of seronegative mothers, although their fathers were
carriers. Furthermore, all serological markers and HBV DNA
detected in utero were strictly linked to the maternal but not
the paternal serological status. Therefore, we consider that
transplacental leakage of the HBV might play a major role in
vertical transmission rather than germ line transmission. The ﬁrst
evidence of transplacental infection with HBV was reported in
1980.26 Placental pathological exam has also demonstrated that
titers of HBV DNA increase gradually from the maternal side to the
fetal side.10–12 The incidences of transplacental leakage have been
found to be increased particularly during uterine contraction and
labor. However, this leakage has rarely occurred during the early
and middle trimesters,14,18 and post-exposure immunoprophy-
laxis is still enormously effective at preventing maternal–fetal
hepatitis B transmission.1 All of the above studies demonstrate that
intrauterine HBV infection would most likely occur during or near
labor rather than via germ cell transmission; this hypothesis was
conﬁrmed by our previous study.27A limitation of this study is that we did not detect integrated
HBV DNA in fetuses. Integrated HBV DNA was found in the
hepatocytes of children with severe hepatitis, and the serological
makers of these children were negative.28 Some authors believe
this is related to the failure of postnatal immunoprophylaxis.29
However, whether this kind of silent infection originates from
ovum transmission would be difﬁcult to conﬁrm in humans
because of ethical considerations. Moreover, in our study, most of
the children born to HBsAg-positive fathers responded better to
the vaccination, and neither acute nor fulminant hepatitis occurred
during the follow-up period. Thus the incidence of such viral
integration still seems very low.
In conclusion, transmission of HBV via the male germ line
appears unlikely in vivo, especially in areas where pre-conception
vaccination is formally recommended. Therefore maternal–fetal
transmission is likely the only major route of vertical transmission
of hepatitis B.
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